| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| References |
: Endoh T, Yagihashi A, Sasaki M, Watanabe N. Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis. Transfusion. 1999 Mar;39(3):306-9. PubMed PMID: 10204595.
|
|---|---|
| Additional Infomation |
7beta-aminocephalosporanic acid is the alpha,beta-unsaturated monocarboxylic acid that is the active nucleus for the synthesis of cephalosporins and intermediates. It is functionally related to a cephalosporanic acid. It is a tautomer of a 7beta-aminocephalosporanic acid zwitterion.
7-Aminocephalosporanic acid has been reported in Apis cerana with data available. |
| Molecular Formula |
C10H12N2O5S
|
|---|---|
| Molecular Weight |
272.27
|
| Exact Mass |
272.046
|
| CAS # |
957-68-6
|
| Related CAS # |
957-68-6
|
| PubChem CID |
441328
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
560.6±50.0 °C at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
292.9±30.1 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.661
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)N)SC1)C(=O)O
|
| InChi Key |
HSHGZXNAXBPPDL-HZGVNTEJSA-N
|
| InChi Code |
InChI=1S/C10H12N2O5S/c1-4(13)17-2-5-3-18-9-6(11)8(14)12(9)7(5)10(15)16/h6,9H,2-3,11H2,1H3,(H,15,16)/t6-,9-/m1/s1 SMILES
|
| Chemical Name |
(6R,7R)-3-(Acetyloxymethyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| Synonyms |
7-ACS 7 ACS 7ACS 7-Aminocephalosporinic acid 7 Aminocephalosporinic acid 7Aminocephalosporinic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~1.1 mg/mL (~4.04 mM)
H2O : ~1.1 mg/mL (~4.04 mM) DMF :< 1 mg/mL DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (3.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6728 mL | 18.3641 mL | 36.7282 mL | |
| 5 mM | 0.7346 mL | 3.6728 mL | 7.3456 mL | |
| 10 mM | 0.3673 mL | 1.8364 mL | 3.6728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02351310 | WITHDRAWN | Drug: Betamethasone Genetic: Placebo |
Premature Birth Preterm Labor |
Pediatrix | 2015-11 | Phase 3 |
| NCT00635102 | COMPLETEDWITH RESULTS | Drug: D-Cycloserine PO and Glycine IV Drug: Placebo D-Cycloserine PO and placebo Glycine IV Drug: Placebo D-Cycloserine PO and Glycine IV Drug: D-Cycloserine PO and placebo Glycine IV |
Alcohol Dependence | Yale University | 1997-10 | Not Applicable |
| NCT04000490 | COMPLETED | Other: SCARE Score | ACS - Acute Coronary Syndrome Assessment Chest Pain |
Centre Hospitalier Régional d'Orléans | 2019-10-01 | |
| NCT05385341 | WITHDRAWN | Other: Telerehabilitation (Tele RCV) Other: Rehabilitation (RCV) |
Acute Coronary Syndrome | University Hospital, Toulouse | 2022-09-01 | Not Applicable |
| NCT02580773 | COMPLETED | Drug: Prophylactic anticoagulation ( INNOHEP®) Drug: Curative anticoagulation ( INNOHEP®) |
Acute Chest Syndrome Anemia Low-Molecular-Weight Heparin Sickle Cell Locations |
Assistance Publique - Hôpitaux de Paris | 2016-12-16 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA